Abstract

MARIN ORTEGA, CRISTHIAN GABRIEL. PROCALCITONIN VERSUS PRESEPSIN IN SEPSIS. Rev Cient Cienc Méd [online]. 2025, vol.28, n.1, pp.37-41.  Epub June 30, 2025. ISSN 1817-7433.

Sepsis, a life-threatening organ dysfunction resulting from a dysregulated host response to infection, requires reliable biomarkers for optimal management. Procalcitonin is the most established biomarker, with high specificity for bacterial infection, usefulness in guiding antibiotic therapy, and correlation with severity. However, its elevation can occur in non-infectious contexts and its accessibility is variable. Presepsin, a marker of monocyte/macrophage activation, is emerging as an alternative, with potentially earlier elevation. However, its interpretation is affected by renal function and its clinical evidence is still limited. Comparative studies indicate similar sensitivities and specificities, although procalcitonin has greater clinical validation. The interpretation of any biomarker must be integrated into the clinical picture, as none is irrefutable. Further multicenter studies are recommended to define the optimal role of each.

Keywords : Sepsis; Biomarkers; Procalcitonin.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )